In lymphoma, NLRP3 inflammasome blockade in vivo suppressed tumor growth and ameliorated antitumor immunity by decreasing MDSCs, TAMs, and Tregs through the effector cytokine IL-18. Here, NLRP3 is linked to neoplasm.